Lixte Biotechnology Files New Patent Application for Treatment of Brain Tumors
Posted on: Friday, 15 August 2008, 09:00 CDT
Lixte Biotechnology Holdings has filed a patent application for the use of compounds the company is developing for treatment of brain tumors as potential treatments for neurodegenerative diseases including Alzheimer's and Parkinson's disease.
John Kovach, president and CEO of Lixte, said: "Lixte has developed a series of novel compounds that inhibit the growth of common brain cancers of adults and children in mouse models. We have now found that some variants of these compounds have effects on brain cells that are believed to be potentially useful for the treatment of common neurodegenerative brain diseases.
"Since Lixte is focused primarily on developing anticancer drugs, we are exploring partnerships with companies that have expertise and research programs in the treatment of Alzheimer's disease."
Source: Datamonitor
Related Articles
- Deep Brain Stimulation May Be Effective Treatment For Tourette's Syndrome
- Stereotactic Radiosurgery For Treating Cancer Patients With Brain Metastases
- Cooling Treatment After Cardiac Arrest Is Cost-effective
- Deep Brain Stimulation Promising Treatment for Cerebral Palsy
- Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
- EpiCept Reports Positive Trials for Brain Tumor Compound
- Blood Supply to Brain is Linked to Dementia
- Problems Linger for Pediatric Brain Cancer Survivors
- Portable Brain Scanner Could Save Stroke Victims' Lives
- Neurologix Licenses Promising New Gene for Treatment of Alzheimer's and Other CNS Disorders
 |
 |
User Comments (0)
RSS Feeds